Intellia Doses First Patient in Phase 3 CRISPR Gene Editing Trial for Hereditary Angioedema

Published: 01/22/2025

Intellia Doses First Patient in Phase 3 CRISPR Gene Editing Trial for Hereditary Angioedema

tags

Latest News

NEWS 05.25.2026

Reviving India’s Surgical Heritage: How Dr. Debabrata Acharjee is Building a Future-Ready Ayurvedic Healthcare Ecosystem – theblunttimes.in

NEWS 05.25.2026

“They’re not alone”: Meet woman helping to restore dignity for fistula survivors – Tuko News

NEWS 05.25.2026

South Korean scientists 3D-print living cornea that could help millions see again – MSN

NEWS 05.25.2026

Senolytic Drug Combination Delays Early Intervertebral Disc Degeneration in Mice – Weekly Voice